NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 7 March 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Paul Arundel (Chair) Present for all items
2. Professor Iolo Doull (Vice – Chair) Present for all items
3. Emtiyaz Chowdhury Present for all items
4. Sarah Davis Items 5 to 5.3.2
5. Carrie Gardner Present for all items
6. Professor Jonathan Ives Present for all items
7. Stuart Mealing Present for all items
8. Dr Shehla Mohammed Items 1 to 4.2.2
9. Sara Payne Present for all items
10. Professor Ed Wilson Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director, Medicines Evaluation Items 4.1.3 to 5.3.2

Linda Landells, Associate Director Items 1 to 4.2.2

Emily Crowe, Associate Director Items 5 to 5.3.2

Kate Moore, Project Manager Items 1 to 4.2.2

Leena Issa, Project Manager Items 5 to 5.3.2

Elizabeth Bell, Health Technology Assessment Adviser Items 1 to 4.2.2

Victoria Kelly, Health Technology Assessment Adviser Items 5 to 5.3.2

Heather Stegenga, Health Technology Assessment Analyst Items 1 to 4.2.2

Sharlene Ting, Health Technology Assessment Analyst Items 5 to 5.3.2

External assessment group representatives present

Isaac Corro Ramos, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3

Robert Wolff, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3

Benjamin Farrar, BMJ Group Items 5 to 5.2.1

Tracey Jhita, BMJ Group Items 5 to 5.2.1

Clinical, Patient & NHS England experts present

Joanne Hanley, Patient expert, nominated by Endometriosis UK, Items 1 to 4.1.3

Dr Karolina Afors, Consultant Obstetrician & Gynaecologist, Clinical expert, nominated by Besins Healthcare UK, Items 1 to 4.1.3

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 5 to 5.3.2

Rosemary Dill, Patient expert, nominated by Myeloma UK, Items 5 to 5.1.4

Karthik Ramasamy, Clinical expert, nominated by UK Myeloma Society, Items 5 to 5.1.4

Scott Purdon, Patient expert, nominated by Myeloma UK, Items 5 to 5.1.4

Neil Rabin, Clinical expert, nominated by UK Myeloma society, Items 5 to 5.1.4

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair Dr Paul Arundel welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Angharad Shambler, Anthony Williams, Tina Garvey and Sarah Davis.

### News and announcements

* 1. The chair noted that Annett Blochberger who hold the role of Pharmacist on the committee will be taking a pause in her tenure, she expects to rejoin Committee in September 2024

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 14 February 2024.

### Appraisal of relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis [ID3982]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Gedeon Richter UK.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10873/documents).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Stuart Mealing, Carrie Gardner and Sara Payne.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10873>

### Appraisal of selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]

* 1. Part 1 – Open session
     1. The chair Dr Paul Arundel welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Menarini Stemline.
     2. The chair noted apologies from Angharad Shambler, Anthony Williams, Dr Shehla Mohammed and Tina Garvey.
     3. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10646)
     4. The Chair led a discussion of the consultation comments presented to the committee.
  2. Part 2a – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  3. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10646>

### Date of the next meeting

The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Wednesday 10 April 2024 and will start promptly at 9am.